Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -229.92% is 29% above its 5-year average of -321.65%, near the high end of its 5-year range (-1221.41%–29.52%).
3.55% above its 12-month average of -238.38%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-229.92%
NET PROFIT MARGIN AVG TTM
-238.38%
NET PROFIT MARGIN AVG 3Y
-363.69%
NET PROFIT MARGIN AVG 5Y
-321.65%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.55%
CURRENT VS 3Y AVG
+36.78%
CURRENT VS 5Y AVG
+28.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-65591.43%
vs the sector median at left
Tango Therapeutics, Inc.
Market Cap
$3.57B
Net Profit Margin
-229.92%
TTM Avg
-238.38%
3Y Avg
-363.69%
5Y Avg
-321.65%
Market Cap
$3.56B
Net Profit Margin
20.37%
TTM Avg
9.12%
3Y Avg
-3.67%
5Y Avg
-13.14%
Market Cap
$3.54B
Net Profit Margin
-4612.13%
TTM Avg
-2306.07%
3Y Avg
-1485.27%
5Y Avg
-1076.43%
Market Cap
$3.52B
Net Profit Margin
-1.69%
TTM Avg
-12.55%
3Y Avg
-19.61%
5Y Avg
-21.06%
Market Cap
$3.64B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.48B
Net Profit Margin
-74.75%
TTM Avg
-1986.54%
3Y Avg
-1142.83%
5Y Avg
-820.99%
Market Cap
$3.44B
Net Profit Margin
-6755.78%
TTM Avg
-10397.28%
3Y Avg
-7288.11%
5Y Avg
-5606.97%
Market Cap
$3.38B
Net Profit Margin
33.42%
TTM Avg
30.07%
3Y Avg
2.48%
5Y Avg
-14.75%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | $3.57B | -229.92% | -238.38% | -363.69% | -321.65% |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 20.37% | 9.12% | -3.67% | -13.14% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | -4612.13% | -2306.07% | -1485.27% | -1076.43% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -1.69% | -12.55% | -19.61% | -21.06% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | 0.00% | 0.00% | 0.00% | 0.00% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -74.75% | -1986.54% | -1142.83% | -820.99% |
| Celcuity Inc. (CELC)vs › | $3.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -6755.78% | -10397.28% | -7288.11% | -5606.97% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 33.42% | 30.07% | 2.48% | -14.75% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-178.4%
Net Profit Margin
-229.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 29.52% |
| 2025-06-30 | -1221.41% |
| 2025-03-31 | -739.54% |
| 2024-12-31 | -914.99% |
| 2024-09-30 | -251.29% |
| 2024-06-30 | -128.56% |
| 2024-03-31 | -585.91% |
| 2023-12-31 | -566.43% |
| 2023-09-30 | -207.45% |
| 2023-06-30 | -141.87% |
| 2023-03-31 | -485.74% |
| 2022-12-31 | -453.28% |
| 2022-09-30 | -419.80% |
| 2022-06-30 | -430.74% |
| 2022-03-31 | -437.79% |
| 2021-12-31 | -385.69% |
| 2021-09-30 | -288.64% |
| 2021-06-30 | -24.75% |
| 2021-03-31 | -189.57% |
| 2020-12-31 | -96.97% |
| 2020-09-30 | 238.01% |
| 2020-06-30 | -165.72% |
| 2020-03-31 | -167.99% |
